A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Author:

Mayer Katharina A.1,Schrezenmeier Eva1,Diebold Matthias1,Halloran Philip F.1,Schatzl Martina1,Schranz Sabine1,Haindl Susanne1,Kasbohm Silke1,Kainz Alexander1,Eskandary Farsad1,Doberer Konstantin1,Patel Uptal D.1,Dudani Jaideep S.1,Regele Heinz1,Kozakowski Nicolas1,Kläger Johannes1ORCID,Boxhammer Rainer1,Amann Kerstin1,Puchhammer-Stöckl Elisabeth1,Vietzen Hannes1,Beck Julia1,Schütz Ekkehard1,Akifova Aylin1,Firbas Christa1,Gilbert Houston N.1,Osmanodja Bilgin1,Halleck Fabian1,Jilma Bernd1,Budde Klemens1,Böhmig Georg A.1ORCID

Affiliation:

1. From the Departments of Medicine III (K.A.M., M.D., M.S., S.H., A.K., F.E., K.D., G.A.B.), Clinical Pathology (H.R., N.K., J.K.), and Clinical Pharmacology (S.S., C.F., B.J.) and the Center of Virology (E.P.-S., H.V.), Medical University of Vienna, Vienna; the Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland (M.D.); the Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin (E.S., S.K., A.A., B.O., F.H., K.B.), MorphoSys, Planegg (R.B....

Funder

Human Biosciences (Hi-Bio), Inc.

Publisher

Massachusetts Medical Society

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3